Kymera Therapeutics Executives and Directors Sell Shares
| Reporter Name | Relationship | Type | Amount | SEC Filing |
|---|---|---|---|---|
| Albers Jeffrey W. | Director | Sell | $311,101 | Form 4 |
| Mainolfi Nello | Chief Executive Officer | Sell | $1,470,000 | Form 4 |
| Ridloff Elena | Director | Sell | $553,200 | Form 4 |
| Esposito Pamela | Director | Sell | $245,185 | Form 4 |
Jeffrey W. Albers, a Director at Kymera Therapeutics, sold 6,349 shares of Common Stock on June 3, 2025, at a price of $49.0 per share, totaling $311,101. Following this transaction, Albers no longer directly owns any shares of Kymera Therapeutics. The sale was executed under a Rule 10b5-1 trading plan adopted on September 20, 2024.
Nello Mainolfi, Kymera Therapeutics' Chief Executive Officer, sold 30,000 shares of common stock on June 3, 2025, at a price of $49.0 per share, totaling $1,470,000. Following the transaction, Mainolfi directly owns 660,482 shares of the company. The sale was conducted under a Rule 10b5-1 trading plan adopted on September 6, 2024.
Elena Ridloff, a Director at Kymera Therapeutics, sold a total of 12,000 shares of Common Stock on June 3, 2025, through two separate transactions at prices of $45.5 and $47.0 per share, totaling $553,200. Following these transactions, Ridloff no longer directly owns any shares of Kymera Therapeutics. These sales were conducted under a Rule 10b5-1 trading plan established on November 25, 2024.
Pamela Esposito, a Director at Kymera Therapeutics, sold 5,000 shares of Common Stock on June 3, 2025, at a weighted average price of $49.0371 per share, totaling $245,185. Following this transaction, Esposito no longer directly owns any shares of Kymera Therapeutics Common Stock.